ಟ್ವೀಟ್ಗಳು
- ಟ್ವೀಟ್ಗಳು
- ಟ್ವೀಟ್ಗಳು & ಪ್ರತಿಕ್ರಿಯೆಗಳು
- ಮಾಧ್ಯಮ
@ASCO ತಡೆಹಿಡಿಯಲಾಗಿದೆ
ನೀವು ಖಚಿತವಾಗಿಯೂ ಈ ಟ್ವೀಟ್ಗಳನ್ನು ನೋಡಲು ಬಯಸುವಿರಾ? ಟ್ವೀಟ್ಗಳನ್ನು ನೋಡುವುದು @ASCO ಅವರನ್ನು ತಡೆತೆರವುಗೊಳಿಸುವುದಿಲ್ಲ.
-
An ASCO Special Article in
@JOP_ASCO highlights our workshop with@NIOSH on the safe handling of hazardous drugs http://bit.ly/2l8jZuQ -
Access videos from
#GU17 on Virtual Meeting http://bit.ly/2kK1FvT#ASCOU -
What has the checkpoint inhibitor experience in melanoma taught us about immunotherapy for other cancers? http://bit.ly/2lvJKZq
#ImmunoSympic.twitter.com/C6YgjF6wYc
-
Diversity & composition of gut microbiome correlates w/response to anti–PD-1
#immunotherapy in melanoma http://bit.ly/2laXLIL#ImmunoSympic.twitter.com/nugQGBkrHn
-
Tumor neoantigens in personalized cancer immunotherapy http://bit.ly/2lvOPRC
#ImmunoSympic.twitter.com/BW1RDvB2gK
-
Resident memory T cells shape distinct immune microenvironments in individual melanoma metastases http://bit.ly/2lQP7mB
#ImmunoSympic.twitter.com/CqLt1P9A4x
-
Aging and Immunity: Is cancer immunotherapy less effective in older patients? http://bit.ly/2lKwtgq
#ImmunoSympic.twitter.com/QZjdVGTflx
-
Visit the ASCO Exhibits today at
#ImmunoSym in Regency Ballroom, Salon U! -
Leveraging Immune Biomarkers in the Blood to Guide
#Immunotherapy: Current Application & Future Prospects http://bit.ly/2lSvuet#ImmunoSympic.twitter.com/cknpubsiIu
-
ASCO Retweeted
#travelban and cancer. As an oncologist it matters. A lot.http://bit.ly/2lA4zS8@ASCO -
Today's the final day of the Multidisciplinary Cancer Management Courses (MCMC) taking place in Morocco: http://bit.ly/2cLmqFr pic.twitter.com/7B9hxKMaCb
-
35% of oncologists are suffering from burnout - here's what we're doing to promote physician wellness: http://bit.ly/2lKgYoF
#ImmunoSympic.twitter.com/9IKZ2afr8Q
-
ASCO Retweeted
@JCO_ASCO launches its newest publication, JCO CCI, with four just-published articles - http://bit.ly/2l4GYHo#informatics#JCOCCI -
Submit your paper on clinical insights from bio-informatics methods applied to oncology data: http://bit.ly/2dzjM4d
#JCOPO -
We've launched a new journal dedicated to precision oncology. Check out the first articles now: http://bit.ly/2lNrDz3
#JCOPOpic.twitter.com/EDDsVEzIVV
-
Evaluating pseudoprogression, atypical responses, and the clinical benefit of cancer immunotherapy http://bit.ly/2lKt8Ov
#ImmunoSympic.twitter.com/WxwQtO5zM5
-
Plinabulin + docetaxel shows potential for improving OS in previously treated NSCLC: http://bit.ly/2mfq0Lk
#immunosympic.twitter.com/B0bjpANrVh
-
Learn about Sanford Health's participation in
#CancerLinQ. Listen now!@HubCity_Newshttp://bit.ly/2m5AJbh -
Cancer immunotherapy: The end of the beginning or the beginning of the end? http://bit.ly/2mhrH7V
#ImmunoSympic.twitter.com/F1fpaS9VQW
-
The Tennessee Oncology Practice Society (TOPS) &
@ASCO strongly support oral chemotherapy parity.
ಲೋಡಿಂಗ್ ಸಮಯ ಸ್ವಲ್ಪ ತೆಗೆದುಕೊಳ್ಳುತ್ತಿರುವಂತೆನಿಸುತ್ತದೆ.
Twitter ಸಾಮರ್ಥ್ಯ ಮೀರಿರಬಹುದು ಅಥವಾ ಕ್ಷಣಿಕವಾದ ತೊಂದರೆಯನ್ನು ಅನುಭವಿಸುತ್ತಿರಬಹುದು. ಮತ್ತೆ ಪ್ರಯತ್ನಿಸಿ ಅಥವಾ ಹೆಚ್ಚಿನ ಮಾಹಿತಿಗೆ Twitter ಸ್ಥಿತಿಗೆ ಭೇಟಿ ನೀಡಿ.
ASCO
Don S Dizon